Novartis AG reported strong quarterly results with a 10% increase in net sales and a 20% rise in core operating income. Key medicines like Entresto and Cosentyx showed significant sales growth, while the prostate cancer drug Pluvicto saw a 50% increase. The company has gained new FDA approvals and continues to focus on innovative medicines, recently investing in molecular glue degrader-based treatments. Teljes cikk (Euronews.com)